tbuckley/cabot-search huggingface dataset:
Genetics
Authors: Raymond L. Teplitz
Journal: JAMA (1980)

<h3>Gene Construction and Modification</h3> As our understanding of genetics and molecular biology deepens, some central concepts have required modification. One of these, the doctrine of one gene—one polypeptide, must now be altered, at least from its simplest form. Hozumi and Tonegawa<sup>1</sup>have found that the gene loci for the constant and variable regions of the<i>k</i>light chain of the Ig molecule are separated in the genome (chromosome) of the embryo but are adjacent in the genome of the adult animal. The experiment first required that the DNA be fragmented by restriction enzyme digestion and the fragments separated according to molecular size by preparative agarose gel electrophoresis. The location of the variable and constant regions was achieved by hybridizing with iodine 125—labeled messenger RNA, prepared from a myeloma tissue culture line (MOPC 321) secreting the relevant light chain. The pattern of labeling obtained with embryonic DNA indicated that the
Attitude—Not Altitude—in Mexico May Endanger Olympic Performances
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GEOGRAPHIC RESTRICTIONS IN ADMISSION TO MEDICAL SCHOOLS
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Variation in <i>TRMT11 </i>gene as a prognostic marker in advanced-stage castrate-resistant prostate cancer (CRPC) patients.
Authors: Ben Yiming Zhang, Douglas W. Mahoney, Shaun M. Riska, James Robert Cerhan, Ricardo Jorge Teixeira Ribeiro, Rui Medeiros, Catia Monteiro, Augusto Nogueira, Joaquina Mauricio, Avelino Manuel Fraga, Fernando Calais-Da-Silva, Brian Addis Costello, Roxana Stefania Dronca, Henry C. Pitot, Timothy Jerome Moynihan, Fernando Quevedo, Manish Kohli
Journal: Journal of Clinical Oncology (2015)

e16114 Background: In a prior study, we found that 8 single nucleotide polymorphisms (SNPs) from 4 candidate hormone-related genes (JAK2, TRMT11, NKX3-1 and HSD17B12) were associated with overall survival (OS) in CRPC stage in a North American cohort of 519 subjects. We attempt to replicate these findings in an independent cohort of Portuguese patients. Methods: A hundred and forty CRPC stage patients in the new cohort were genotyped for the candidate SNPs. The primary endpoint was overall survival (OS), defined as time from development of CRPC to death. For SNP level results we estimated hazard ratios (HR) and 95% confidence intervals (CI) under the dominant allele model using Cox regression and adjusted for age and Gleason score (GS). Results: The median age of the Portuguese cohort was 69 years (range 53-84). The GS distribution was 48% subjects with GS ≥ 8; 35% with GS = 7 and 17% with GS < 7. Median time from castration resistance to death for the cohort was 2.2 years (IQ range: 0.8-3.4, 93 deaths). One of the 3 SNPs (rs2295005; C > G; MAF = 0.16) in the TRMT11 gene was associated with OS after adjustment for age and GS: (dominant model p = 0.05, HR = 0.56; 95 CI = 0.31-1.00). No other SNP was observed to have statistical significance with OS (Table). Conclusions: Variation in the TRMT11 gene is significantly associated with overall survival in patients with CRPC and warrants further validation as a potential prognostic biomarker. SNP Gene HR ( C.I.) Adjusted p-value rs2295005 TRMT11 0.55 (0.30-1.00) 0.05 rs1268121 TRMT11 1.41 (0.87-2.28) 0.15 rs9388462 TRMT11 1.47 (0.82-2.61) 0.19 rs7005368 NKX3.1 0.94 (0.49-1.82) 0.87 rs11037662 HSD17B12 1.24 (0.74-2.08) 0.4 rs437063 JAK2 1.14 (0.69-1.88) 0.58 rs10503733 NKX3.1 1.06 (0.67-1.68) 0.79 rs3808850 JAK2 0.98 (0.62-1.53) 0.93
Teen-Age Volunteers Aid Physicians In Unusual Program for Mentally Ill
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.
Authors: Jason Edward Faris, Lawrence Scott Blaszkowsky, Eunice Lee Kwak, David Tsai Ting, Andrew X. Zhu, Jeffrey W. Clark, Jill N. Allen, Hui Zheng, Dan G. Duda, Theodore S. Hong, Jennifer Yon-Li Wo, Janet E. Murphy, Lipika Goyal, Jeffrey A. Meyerhardt, Nadine Jackson McCleary, Kimmie Ng, Jennifer A. Chan, Charles S. Fuchs, David P. Ryan, Matthew Kulke
Journal: Journal of Clinical Oncology (2014)

TPS4157 Background: Neuroendocrine tumors are highly vascularized cancers. Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), whose targets include vascular endothelial growth factor receptors (VEGFRs) and stem-cell factor receptor (c-KIT), was recently approved for the treatment of patients with pancreatic neuroendocrine tumors (PNET). PNETs often express c-KIT, and more than half of PNET metastatic to lymph nodes or liver express MET, which is a putative mechanism of resistance to VEGF inhibitors. We are conducting a phase II trial of cabozantinib, a TKI with activity against VEGFRs, MET, RET, and KIT, which is approved for advanced medullary thyroid cancer. Cabozantinib has been demonstrated to inhibit development of hepatic metastases, with improved survival compared to VEGF inhibitor treatment in the RIP-Tag2 transgenic mouse model of PNET. Methods: The study is an open-label Phase II trial, with planned enrollment of 35 patients to each of two cohorts for patients with carcinoid and PNET. Eligible patients must have well or moderately differentiated tumors, and patients must be receiving or have progressed on octreotide if a carcinoid tumor. Patients receive 60mg of cabozantinib daily in 28-day cycles. The primary objective of this study is to evaluate the activity of cabozantinib in patients with PNET and carcinoid tumors as assessed by overall response rate (ORR). Secondary objectives include evaluation of progression free survival and overall survival, as well as correlative studies of circulating tumor cells and pro-angiogenic biomarkers at baseline and on-treatment. Imaging is performed every two cycles for the first three months, followed by every three cycles. For both cohorts, we hypothesize that cabozantinib will have an ORR≥12%. A sample size of 35 in each cohort achieves >80% power to detect a difference of 10% in ORR using a one-sided binomial test, with type I error of 3% and population proportion under the null hypothesis of 2%. Results and Conclusions: As of January 26, 2013, 31/70 (44%) of planned patients have been enrolled: 18 with carcinoid, and 13 with PNET. Clinical trial information: 01466036.
“Health” Steak
Authors: George F. Cahill
Journal: New England Journal of Medicine (1973)

A simple nutritional experiment that can be done in many households is to count sunflower seeds offered to the children's gerbil or hamster. The adult animal will eat just so many a day and cache the remainder in some hidden spot in the cage. If the exercise wheel is removed, fewer seeds will be eaten and more hidden. If many extra seeds are offered, a few more will be eaten to provide the extra calories consumed in transporting and hiding the surplus! In any case, the animal's weight does not change provided basal caloric needs are met.Campbell, Van Itallie . . .
THE FUNCTIONS OF THE STOMACH AFTER GASTROSTOMY.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Lasker Awards at fifty
Authors: M. E. DeBakey
Journal: JAMA (1995)

This year marks the 50th anniversary of the Albert Lasker Medical Research Awards, presented by the Albert and Mary Lasker Foundation. Created to recognize outstanding contributions to the medical sciences, the Lasker Awards ceremony is an auspicious occasion in the career of every honoree awarded the Winged Victory statuette. In the keen vision of Mary Lasker, however, the prestige of winning was subordinated to her principal goal—fostering support for biomedical research. By establishing separate awards for basic research, clinical research, and public service, Mary Lasker sought to emphasize the social foundations of science, reasoning that the public, once aware of the benefits of medical research, would willingly and generously provide its financial support. Among the world's honors for research accomplishment, the Lasker Awards are the embodiment of the peer-review process. Juries charged with choosing the winners comprise preeminent scientists, many of whom have themselves received the Lasker Award and the
Carcinoma of the Breast
Authors: Francis D. Moore, Steven I. Woodrow, Menelaos A. Aliapoulios, Richard E. Wilson
Journal: New England Journal of Medicine (1967)

THERE can be no doubt of the growing importance of breast cancer. This tumor stands unique as the commonest malignant tumor of middle-aged women, and the leading cause of death in white women in the United States, thirty-nine to fifty-four years of age. No single manifestation of cardiovascular or renal disease, no single infection and no complication of pregnancy or parturition takes such a toll of the mother in her prime.Twelve years ago, in an effort to improve the care of patients suffering from carcinoma of the breast, a group activity was established at this hospital, functioning as a . . .
Self management of arthritis in primary care: randomised controlled trial
Journal: BMJ (2006)

Objective To evaluate clinical effectiveness of a self management programme for arthritis in patients in primary care with osteoarthritis.Design Randomised controlled trial.Setting 74 general practices in the United Kingdom.Participants 812 patients aged 50 and over with osteoarthritis of hips or knees (or both) and pain or disability (or both).Intervention Participants were randomised to six sessions of self management of arthritis and an education booklet (intervention group) or the education booklet alone (control group).Main outcome measures Primary outcome was quality of life, as assessed by the short form health survey (SF-36).Several other physical and psychosocial secondary outcomes were assessed.Data were collected at baseline, four months, and 12 months.Results Response rates were 80% and 76% at four and 12 months.The two groups showed significant differences at 12 months on the anxiety subscore of the hospital anxiety and depression scale (mean difference -0.62, 95% confidence interval -1.08 to -0.16), arthritis self efficacy scale for pain (0.98, 0.07 to 1.89), and self efficacy for other aspects of management (1.58, 0.25 to 2.90).Results were similar for intention to treat and per protocol analyses.No significant difference was seen in number of visits to the general practitioner at 12 months.Conclusions The self management of arthritis programme reduced anxiety and improved participants' perceived self efficacy to manage symptoms, but it had no significant effect on pain, physical functioning, or contact with primary care.Trial registration Current Controlled Trials ISRCTN79115352. Methods PracticesPeople with osteoarthritis were recruited from UK general practices in areas where the voluntary organisation Arthritis Care provided the "challenging arthritis" intervention.This is a programme for self management of arthritis developed from the original US model based on social cognitive theory, in which self efficacy plays an important part (see box A on bmj.com). 7We identified general practices that belonged to the Medical Research Council's research framework and, in areas where this was not possible, we approached local primary care research networks.Trained research nurses recruited practice participants. RecruitmentWe recruited participants between December 2000 and February 2003.Twelve month follow-up for all participants ended in March 2004.
Autoimmunity in concurrent myasthenia gravis and pemphigus erythematosus
Authors: E. H. Beutner
Journal: JAMA (1968)

A patient with myasthenia gravis, a malignant thymoma, and pemphigus erythematosus was found to have antibodies to the cross striations of skeletal muscle, to the intercellular areas of stratified squamous epithelium, and to nuclei as revealed by indirect immunofluorescence. Somewhat comparable observations have been made in other cases. The concurrence of these rare immunologic derangements point to some common underlying mechanisms.
BOOKS IN REVIEW 1992
Authors: ERIC J. SEIFTER
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article BOOKS IN REVIEW 1992 Get access Atlas of Diagnostic Oncology . Arthur T. Skarin , ed. Philadelphia : J. B. Lippincott , 1991 . 450 pp., illus. $139.50. Reviewed by Kevin R. Fox (first citation) and Scott M. Lippman (second citation) (JNatl Cancer Inst 84: 1205–1206 , 1992 ). ERIC J. SEIFTER ERIC J. SEIFTER Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 2, 20 January 1993, Pages 159–160, https://doi.org/10.1093/jnci/85.2.159-d Published: 20 January 1993
Un-cross-matched blood for emergency transfusion. One year's experience in a civilian setting
Authors: N. Blumberg
Journal: JAMA (1978)

One year's experience (56 cases) in the use of un-cross-matched blood for emergency transfusion in a large civilian teaching hospital showed that 49 transfusions were given as un-cross-matched, group-specific (ABO and Rh) blood in emergencies. Seventy-seven percent (43) of blood requests were for patients with trauma, unexpected massive intraoperative hemorrhage, or ruptured aneurysm. The indications for emergency transfusion were questionable in ten cases. There were no adverse effects noted even though complete serologic testing had not been done. While the use of un-cross-matched blood is usually safe, the potential for serious reaction exists. Overuse should be discouraged. (<i>JAMA</i>240:2057-2059, 1978)
Biphasic Removal of DNA Adducts in a Repetitive DNA Sequence after Dietary Administration of 2-Acetylaminofluorene
Authors: Sandra J. Culp, Miriam C. Poirier, Frederick A. Beland
Journal: Environmental Health Perspectives (1993)

Dietary administration of the hepatocarcinogen 2-acetylaminofluorene (2-AAF) to rats results in the formation of a major hepatic DNA adduct, N-(deoxyguanosin-8-yl)-2-aminofluorene (dG-C8-AF). In liver DNA, dG-C8-AF reaches steady-state conditions after approximately 2 weeks of feeding and is removed in a biphasic manner. In these experiments, we have quantified adduct concentrations in a 370 base-pair repetitive DNA fragment to determine if the adduct levels and kinetics of adduct removal were similar to those found in total genomic DNA. Male F344 rats were fed 0.02% 2-AAF for 28 days and were sacrificed at intermittent times up to 56 days after being returned to the control diet. Hepatic DNA adduct levels were measured by 32P-postlabeling or radioimmunoassay (RIA) in total genomic DNA and in a 370 base-pair fragment obtained by digesting genomic DNA with Hind III. Biphasic removal of dG-C8-AF, which composed about 90% of the total adducts measured, was observed in total genomic DNA, with comparable rate constants being detected by both 32P-postlabeling and RIA. 32P-Postlabeling also showed analogous biphasic removal of dG-C8-AF in the 370 base-pair fragment. A second adduct, 3-(deoxyguanosin-N2-yl)-2-AAF (dG-N2-AAF), which accounted for about 10% of the total adducts measured, showed similar biphasic removal kinetics in the total genomic DNA and the 370 base-pair fragment; however, as compared to dG-C8-AF, little removal of dG-N2-AAF was observed during the slow phase.
Marihuana
Authors: Gabriel G. Nahas
Journal: JAMA (1975)

"MARIHUANA is no more dangerous than alcohol or cigarettes and should be legalized for anyone over the age of sixteen." So declared Margaret Mead in 1968. Ever since, similar statements have been made with increasing regularity by others who wish to see the use of marihuana legalized, or at the very least "decriminalized." And yet, in that same year, 1968, a joint statement was issued by the Committee on Drug Dependence of the National Research Council, National Academy of Sciences, and the American Medical Association, stressing the following points: Cannabis is a dangerous drug and a public health concern. In virtually all societies where it has been extensively used, sanctions against both users and distributors have been necessary. Legalization of marihuana would create a serious abuse problem in the United States. Penalties for violations of marihuana laws are too harsh. They should therefore be modified to penalize
Abstract 3494: Centrobin is involved in the cellular response to DNA damage
Authors: Na-mi Ryu, Jin Ki Jung, Seok Won Jang, Jung Min Kim
Journal: Cancer Research (2019)

Abstract DNA-repair proteins have been found to localize to the centrosomes and defects in these proteins cause centrosome over-duplication. Centrobin is a centriole-associated protein that is required for centriole duplication. In the present study, we investigated a possible role of centrobin in DNA damage response. Centrobin was phosphorylated in response to UV radiation and its phosphorylated form was detected only in the detergent / DNase 1-resistant fraction. UV-induced phosphorylation of centrobin was significantly decreased by ATR inhibition, but not by ATM inhibition. In addition, centrobin-depleted cells showed reduced survival rate after UV exposure compared with control cells. Moreover, centrobin knockdown in DR-GFP/U2OS cells had a significant reduction in DNA repair efficiency of homologous recombination (HR) and this defect was recovered by expression of wild-type centrobin, but not by a mutant form of centrobin. Taken together, these results suggest that centrobin may play a critical role in DDR and that ATR dependent phosphorylation of centrobin may be at least partially responsible for this function. Citation Format: Na-mi Ryu, Jin Ki Jung, Seok Won Jang, Jung Min Kim. Centrobin is involved in the cellular response to DNA damage [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3494.
Pentazocine Fever
Authors: Glen R. Hodges
Journal: JAMA (1971)

<h3>To the Editor.—</h3> Pentazocine was introduced for clinical use in this country in 1967, as an analgesic with an effect similar to the opioids, but with little or no abuse potential. Since its introduction, it has received wide clinical acceptance as an analgesic at the Ohio State University Hospital. Its side effects in our experience have been limited primarily to nausea and occasional vomiting. The purpose of this report is to describe a case of pentazocinerelated fever, a side effect of this drug not previously reported, to our knowledge. <h3>Report of A Case.—</h3> A 24-year-old white man was admitted to University Hospital on Oct 14, 1970, for evaluation of an unexplained fever of 11 days' duration. The patient developed persistent pain in the lower part of the back following an automobile accident in 1967. On evaluation at University Hospital in June 1970, spondylolysis of the L-5 vertebra was found. He